WASHINGTON, Dec. 11, 2017 /PRNewswire-USNewswire/ -- The
College of American Pathologists (CAP) today issued the following
statement from CAP President R. Bruce
Williams, MD, FCAP, after the American Clinical Laboratory
Association (ACLA) filed a lawsuit alleging the agency overseeing
the Medicare program did not follow the Protecting Access to
Medicare Act (PAMA) of 2014 when implementing market-based payment
reforms to clinical laboratory services:
The CAP applauds the ACLA's latest effort urging the Centers for
Medicare & Medicaid Services (CMS) to set aside regulation used
to set clinical laboratory fee schedule rates for 2018. In the
implementation of the PAMA statute, the CAP believed there were
serious flaws in the underlying data collection and methodology to
calculate the clinical laboratory fees. Specifically, the CMS'
methodology excluded many laboratories, including most hospital
outreach laboratories and physician office laboratories that
provide necessary laboratory services ensuring the welfare of
patients. To address these concerns, the CAP and other stakeholders
have strongly urged the CMS to delay its implementation of the
payment system.
About the College of American Pathologists
As the
world's largest organization of board-certified pathologists and
leading provider of laboratory accreditation and proficiency
testing programs, the College of American Pathologists (CAP) serves
patients, pathologists, and the public by fostering and advocating
excellence in the practice of pathology and laboratory medicine
worldwide. For more information, read the CAP Annual Report at
CAP.org.
View original content with
multimedia:http://www.prnewswire.com/news-releases/statement-by-cap-president-r-bruce-williams-md-fcap-on-acla-litigation-regarding-pama-300569860.html
SOURCE College of American Pathologists